Patent classifications
C07D475/10
Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
There is provided a compound of formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
Pteridines useful as HCV inhibitors and methods for the preparation thereof
The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
Pteridines useful as HCV inhibitors and methods for the preparation thereof
The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
MODULATORS OF TOLL-LIKE RECEPTORS
Provided are modulators of TLRs of Formula II:
##STR00001##
pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
MODULATORS OF TOLL-LIKE RECEPTORS
Provided are modulators of TLRs of Formula II:
##STR00001##
pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
COMPOUNDS AS MODULATORS OF ROR GAMMA
The present invention encompasses compounds of the formula (I)
##STR00001##
wherein the variables are defined herein which are suitable for the modulation of ROR and the treatment of diseases related to the modulation of ROR. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
COMPOUNDS AS MODULATORS OF ROR GAMMA
The present invention encompasses compounds of the formula (I)
##STR00001##
wherein the variables are defined herein which are suitable for the modulation of ROR and the treatment of diseases related to the modulation of ROR. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
There is provided a compound of formula I:
##STR00001##
or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
There is provided a compound of formula I:
##STR00001##
or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF
The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.